Results 251 to 260 of about 587,145 (314)
Correction: CRISPR/Cas9-mediated activation of NR5A1 steers female human embryonic stem cell-derived bipotential gonadal-like cells towards a steroidogenic cell fate. [PDF]
Danti L+6 more
europepmc +1 more source
Medical report of the Gynecological department of the faculty obstetric-gynecological clinic
В. В. Владимиров
openalex +2 more sources
What's New? The World Health Organization's Global Breast Cancer Initiative set the benchmark to diagnose breast cancer within 2 months of the first contact with a health care provider. This study analyzed the diagnostic journey of women with breast symptoms at five Ethiopian hospitals. Of the 345 women interviewed who received a diagnostic workup of a
Friedemann Rabe+12 more
wiley +1 more source
Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm. [PDF]
Morisada T+17 more
europepmc +1 more source
What's New? Women who are at high risk of breast cancer (BC), either because of a BRCA1/2 mutation or family history, require more aggressive screening. Here, the authors report on the clinical characteristics of the high‐risk women who developed BC during the TESTBREAST study. Of the 1108 participants, 124 (16.5%) developed breast cancer. Their median
Layla Andour+40 more
wiley +1 more source
Torsion Giant ovarian cysts in a postmenopausal woman with cervical cancer. [PDF]
Tjokroprawiro BA+2 more
europepmc +1 more source
What's New? About half of penile squamous cell carcinomas are causally associated with inflammatory conditions such as lichen sclerosus (LSc), but few large‐scale studies have assessed the risk of penile cancer in men with LSc. Here, the authors conducted a large nationwide study in Denmark to estimate the risk of penile and non‐penile cancer in men ...
Marianne Gardar Stærk+5 more
wiley +1 more source
Correlation of GPA with Final MBBS Examination Scores Among Students on Three Campuses of the University of the West Indies. [PDF]
Kumar A+6 more
europepmc +1 more source
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart+26 more
wiley +1 more source